Skip to content
DaveManuel.com · Institutional Ownership · 13F Holdings

Stonepine Capital Management, LLC

Reported holdings as of Q2 2026, from 31 quarterly filings.

CIK
1440771
Reported value
$177.3M
Positions
83
Top 10 weight
49.4%
Filed
2026-08-17
Days after quarter end
48

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
EVOLUS INC CALLEOLS$14.2M1,590,1628.00%+4.42pp16q-9.6%-$1.5M
ADMA BIOLOGICS INC CALLADMA$14.1M740,0007.98%+1.16pp19qHELD
VERASTEM INCVSTM$12.8M3,349,6277.22%+0.21pp8q+1.4%+$180.8K
TENAX THERAPEUTICS INCTENX$9.6M660,0005.42%-0.83pp3q-32.3%-$4.6M
NEKTAR THERAPEUTICSNKTR$8.4M120,6544.75%+2.30pp5q+41.9%+$2.5M
ULTRAGENYX PHARMACEUTICAL IN CALLRARE$6.3M25,0003.57%-newNEW
CAMP4 THERAPEUTICS CORP COMCAMP$6.1M1,389,6223.43%+0.97pp3qHELD
INSMED INC CALLINSM$5.6Moptions only3.16%-newOPTIONS
ELOXX PHARMACEUTICALS INC COMELOX$5.5M397,1603.11%-newNEW
KAZIA THERAPEUTICS LTDKZIA$4.9M345,1792.74%+1.71pp3qHELD
MEDTRONIC PLC CALLMDT$4.4Moptions only2.47%-newOPTIONS
INDIVIOR PHARMACEUTICALS INCINDV$4.1M100,0002.31%-newNEW
CORBUS PHARMACEUTICALS HLDGSCRBP$4.0M425,0002.25%+0.81pp3q+10.8%+$389.6K
ABBOTT LABORATORIES CALLABT$3.8Moptions only2.14%-newOPTIONS
SATELLOS BIOSCIENCE INCMSLE$3.7M491,6242.10%+1.88pp2q+391.6%+$3.0M
ZEVRA THERAPEUTICS INCZVRA$3.7M258,7012.09%+0.30pp8q-46.1%-$3.2M
ABEONA THERAPEUTICS INCABEO$3.4M557,2841.94%+0.42pp5q-25.4%-$1.2M
BOSTON SCIENTIFIC CORP CALLBSX$3.2Moptions only1.83%-newOPTIONS
EDESA BIOTECH INC COM NEWEDSA$3.2M456,4391.80%+1.74pp4q+1421.5%+$3.0M
BIOMARIN PHARMACEUTICAL INC CALLBMRN$3.1Moptions only1.76%-newOPTIONS
CABALETTA BIO INCCABA$2.9M917,1001.61%+1.56pp3q+1734.2%+$2.7M
AN2 THERAPEUTICS INC COMANTX$2.7M551,6921.51%+0.53pp5q-22.7%-$784.8K
XILIO THERAPEUTICS INCXLO$2.2M225,9941.22%+1.01pp2q+252.2%+$1.6M
ADICET BIO INCACET$2.1M245,5181.20%+0.59pp3q+10.6%+$203.6K
XERIS BIOPHARMA HOLDINGS INC CALLXERS$2.1Moptions only1.18%+0.44pp2qOPTIONS
Tela Bio IncTELA$2.0M2,662,4271.13%+0.48pp13q+1.7%+$33.9K
AYTU BIOPHARMA INCAYTU$2.0M912,9211.11%+0.24pp13q+15.2%+$259.4K
CURIS INCCRIS$1.7M3,312,1850.98%+0.16pp3q-11.1%-$216.3K
HERON THERAPEUTICS INC CALLHRTX$1.7M490,7870.96%+0.19pp7q-65.0%-$3.2M
SPRUCE BIOSCIENCES INC COM NEWSPRB$1.6M28,7950.88%-newNEW
SI-BONE INC CALLSIBN$1.5Moptions only0.85%+0.26pp2qOPTIONS
OKYO PHARMA LTD SHS NEWOKYO$1.3M862,9960.73%+0.18pp2q+1.5%+$19.5K
NEUMORA THERAPEUTICS INC. CALLNMRA$1.2Moptions only0.71%+0.24pp2qOPTIONS
PASITHEA THERAPEUTICS CORKTTA$1.1M2,201,4680.64%+0.39pp3q+164.8%+$706.2K
SOL GEL TECHNOLOGIESSLGL$1.1M14,4690.61%-0.28pp2q-47.9%-$986.7K
PULMONX CORPLUNG$1.1M815,4360.60%+0.20pp5q+6.1%+$61.3K
X4 PHARMACEUTICALS INCXFOR$1.1M224,9890.59%+0.04pp4q-32.9%-$515.2K
ARDELYX INC CALLARDX$1.1Moptions only0.59%+0.23pp2qOPTIONS
DELCATH SYS INC CALLDCTH$1.0Moptions only0.56%+0.19pp3qOPTIONS
IN8BIO INC COM NEWINAB$980.4K695,2870.55%+0.16pp5q+4.8%+$44.9K
MOONLAKE IMMUNOTHERAPEUTICSMLTX$973.5K50,0000.55%-newNEW
QUOIN PHARMACEUTICALS LTDQNRX$965.5K199,4860.54%+0.40pp3q+273.2%+$706.8K
MAXCYTE INCMXCT$924.5K751,6060.52%+0.24pp4q-25.2%-$311.3K
PHATHOM PHARMACEUTICALS INCPHAT$922.4K85,0100.52%+0.30pp2q+70.0%+$379.7K
AZITRA INCAZTR$886.9K5,285,4760.50%-newNEW
CONNECT BIOPHARMA HLDGS LTDCNTB$866.9K364,2540.49%+0.16pp2q+17.5%+$129.1K
CYBIN INCHELP$854.5K129,2800.48%+0.22pp3q-3.6%-$31.6K
INHIBIKASE THERAPEUTICS INCIKT$804.2K396,1790.45%-0.19pp7q-58.6%-$1.1M
ZENTALIS PHARMACEUTICALS INCZNTL$783.7K161,5830.44%+0.19pp6q-40.0%-$521.5K
CYTOMX THERAPEUTICS INCCTMX$768.8K205,0000.43%-0.32pp2q+2.5%+$18.8K
MANNKIND CORP CALLMNKD$750.0Koptions only0.42%-0.08pp4qOPTIONS
NUVECTIS PHARMA INCNVCT$735.6K40,0000.41%-newNEW
CRESCENT BIOPHARMA INC.CBIO$720.0K40,0000.41%-0.22pp3q-52.9%-$810.0K
PMV PHARMACEUTICALS INCPMVP$718.4K536,0860.41%+0.05pp7q-24.3%-$230.5K
ORUKA THERAPEUTICS INCORKA$713.8K7,5000.40%-newNEW
RADIOPHARM THERANOSTICS LTD?RADX$670.5K51,000,000?0.38%+0.08pp3q
ONKURE THERAPEUTICS INCOKUR$595.9K130,6840.34%+0.12pp2q-1.4%-$8.6K
NERVGEN PHARMA CORPNGEN$559.7K271,6780.32%-newNEW
CALCIMEDICA INCCALC$544.9K622,4320.31%-newNEW
ARVINAS INCARVN$498.6K60,0000.28%+0.16pp2q+118.2%+$270.1K
BIOAGE LABS INCBIOA$490.2K20,0000.28%-0.07pp6q-60.0%-$735.3K
Opus Genetics, Inc.IRD$414.0K100,7180.23%+0.11pp2q+46.6%+$131.6K
QT Imaging Holdings, Inc.QTI$407.0K100,0000.23%-newNEW
BOUNDLESS BIO INC COMBOLD$386.5K154,5950.22%-0.05pp5q-74.1%-$1.1M
SINTX TECHNOLOGIES INCSINT$332.5K209,2050.19%-newNEW
CELLECTAR BIOSCIENCES INCCLRB$290.6K104,5500.16%-newNEW
Eupraxia Pharmaceuticals IncEPRX$287.5K43,4910.16%-newNEW
SAB BIOTHERAPEUTICS INCSABS$285.8K73,2710.16%+0.08pp2q+46.5%+$90.8K
ADLAI NORTYE LTDANL$279.0K24,2570.16%-newNEW
SENSEONICS HLDGS INCSENS$276.5K48,6800.16%-newNEW
PLIANT THERAPEUTICS INCPLRX$262.8K230,5380.15%+0.03pp4q+2.6%+$6.7K
CODEXIS INCCDXS$247.8K109,6620.14%-0.13pp4q-73.8%-$696.8K
PRECISION OPTICS CORP INC MASS COM NEWPOCI$236.6K46,3900.13%-0.04pp2q-53.6%-$273.4K
UPSTREAM BIO INCUPB$231.3K33,4320.13%flat2q-4.5%-$10.9K
REIN THERAPEUTICS INCRNTX$226.8K218,0380.13%-newNEW
CNS PHARMACEUTICALS INCCNSP$198.7K41,5730.11%+0.05pp3q-31.8%-$92.9K
HUMACYTE INCHUMA$180.5K231,2990.10%-newNEW
KALARIS THERAPEUTICS INCKLRS$122.6K30,1220.07%+0.02pp2q+47.7%+$39.6K
PROCESSA PHARMACEUTICALS INCPCSA$105.6K55,0000.06%flat3qHELD
BioAtla IncBCAB$68.0K16,4320.04%-newNEW
COMPUGEN LTDCGEN$67.2K31,3870.04%-0.05pp3q-69.9%-$156.0K
OVID THERAPEUTICS INCOVID$57.3K21,3000.03%flat3q-46.8%-$50.3K
EVAXION ASEVAX$54.4K17,5620.03%flat3q-10.9%-$6.7K

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 91.7%Medical Devices 8.0%Other sectors 0.3%
 
SectorValueShare
Biotech & Pharma$161.9M91.7%
Medical Devices$14.2M8.0%
Other sectors$524.3K0.3%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+8.4%+14.8%-6.4%84%
Q1 2026-11.6%-4.6%-7.0%94%
Q4 2025+8.9%+2.4%+6.5%100%
Q3 2025+17.4%+7.8%+9.6%95%
Q2 2025+4.2%+10.5%-6.2%79%
Q1 2025-8.0%-4.6%-3.5%100%
Q4 2024-4.2%+2.1%-6.3%97%
Q3 2024+41.5%+5.4%+36.0%81%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$177.3M832423291349.4%48
Q1 2026$249.7M722318261574.9%44
Q4 2025$137.0M642912172355.3%44
Q3 2025$123.0M581922161962.1%44
Q2 2025$101.9M582024142859.4%44
Q1 2025$102.8M66231822958.1%44
Q4 2024$123.9M52221316858.9%45
Q3 2024$158.2M3817125469.2%44
Q2 2024$109.6M251248787.3%52
Q1 2024$126.1M20847492.3%45
Q4 2023$231.2M160211795.3%44
Q3 2023$301.0M235132383.9%44
Q2 2023$277.2M21686784.2%42
Q1 2023$298.2M22796486.1%42
Q4 2022$237.7M19666690.7%45
Q3 2022$222.4M19168787.8%41
Q2 2022$214.9M254118774.4%43
Q1 2022$241.1M28898374.6%46
Q4 2021$217.9M2381321683.5%45
Q3 2021$219.8M319147481.3%43
Q2 2021$191.2M2631112679.1%47
Q1 2021$185.1M2914114673.1%44
Q4 2020$130.6M21768381.5%43
Q3 2020$96.1M17637288.7%44
Q2 2020$51.6M133191795.8%44
Q1 2020$94.6M271098659.9%44
Q4 2019$143.5M2371151081.8%44
Q3 2019$103.0M267513676.7%44
Q2 2019$145.2M253128875.3%44
Q1 2019$173.9M301549768.6%44
Q4 2018$113.9M22000077.2%44

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.